Master Alliance Provisions Guide (MAPGuide)

BMGF – CureVac – GSK, Letter Agreement for Alignment on Global Access Commitments

  • Term & termination | Term of agreement

2. The release set forth in Section 1 above shall remain in effect with respect to a CLA Product for as long as a vaccine or medicine of that nature is in development or being commercialized under the CLA. For clarity, the release in Section 1 above shall terminate as to any vaccine or medicine for which GSK has terminated the development or commercialisation in accordance with the CLA.